Vandria Raises Second Series A; Round Totals $30.7M

▤ Summary

Vandria, a Lausanne, Switzerland-based mitochondrial therapeutics company, raised an undisclosed amount in its second Series A funding. The round, which brought the total amount to $30.7M, saw participation from Hevolution Foundation and Dolby Family Ventures joined ND Capital. Led by Klaus Dugi, CEO, Vandria is a mitochondrial therapeutics company, developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. The company is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases. A separate program targets ferroptosis, a form of cell death implicated in neurodegenerative diseases and ischemia reperfusion injury.

▦ Linked Companies